Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Journal of Breast Cancer ; : 141-148, 2019.
Article Dans Anglais | WPRIM | ID: wpr-738408

Résumé

The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patients with triple-negative breast cancer (TNBC). However, very little is known about the efficacy of this strategy in male patients with TNBC. In this report, we describe a male patient with AR-positive TNBC who was successfully treated using an LHRH agonist after pretreatment with several lines of chemotherapy and achieved a durable response. We also review the existing evidence supporting LHRH- and AR-targeted therapy for this rare disease.


Sujets)
Femelle , Humains , Mâle , Mâle , Tumeur du sein de l'homme , Traitement médicamenteux , Hormone de libération des gonadotrophines , Goséréline , Lutéine , Maladies rares , Récepteurs aux androgènes , Tumeurs du sein triple-négatives
SÉLECTION CITATIONS
Détails de la recherche